Stockscreener 앱 받기
9.13
1.67%
0.15
시간 외 거래:
9.01
-0.12
-1.31%
전일 마감가:
$8.98
열려 있는:
$8.97
하루 거래량:
633.43K
Relative Volume:
0.60
시가총액:
$1.01B
수익:
-
순이익/손실:
$-227.05M
주가수익비율:
-4.15
EPS:
-2.2
순현금흐름:
$-177.93M
1주 성능:
+2.58%
1개월 성능:
-25.41%
6개월 성능:
+13.70%
1년 성능:
+40.03%
1일 변동 폭
$8.88
$9.30
1주일 범위
$8.56
$9.30
52주 변동 폭
$3.67
$12.61
코젠트 바이오사이언시스 Stock (COGT) Company Profile
명칭
Cogent Biosciences Inc
전화
617-945-5576
주소
275 WYMAN STREET, WALTHAM
COGT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| COGT | 9.13 | 1.01B | 0 | -227.05M | -177.93M | -2.20 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
코젠트 바이오사이언시스 Stock (COGT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | 개시 | Citigroup | Buy |
| 2023-12-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-12-08 | 개시 | JP Morgan | Overweight |
| 2023-04-28 | 개시 | Robert W. Baird | Outperform |
| 2023-03-27 | 재개 | H.C. Wainwright | Buy |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-06-28 | 개시 | Guggenheim | Buy |
| 2021-10-11 | 개시 | H.C. Wainwright | Buy |
| 2021-06-09 | 재개 | Jefferies | Buy |
| 2020-12-23 | 개시 | Piper Sandler | Overweight |
| 2020-10-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
코젠트 바이오사이언시스 주식(COGT)의 최신 뉴스
Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $21.00 at JPMorgan Chase & Co. - Defense World
What is Leerink Partnrs' Estimate for COGT FY2024 Earnings? - MarketBeat
FY2024 EPS Forecast for Cogent Biosciences Lifted by Analyst - Defense World
Trend Tracker for (COGT) - Stock Traders Daily
Cogent Biosciences (NASDAQ:COGT) Shares Down 7%Should You Sell? - MarketBeat
Lifesci Capital Has Negative Outlook of COGT FY2024 Earnings - Defense World
Equities Analysts Offer Predictions for COGT FY2024 Earnings - Defense World
Leerink Partnrs Has Strong Forecast for COGT FY2027 Earnings - MarketBeat
Wedbush Research Analysts Lower Earnings Estimates for COGT - MarketBeat
FY2024 Earnings Estimate for COGT Issued By Lifesci Capital - MarketBeat
COMMODORE CAPITAL LP's Strategic Acquisition in Cogent Biosciences Inc - GuruFocus.com
Wedbush Reaffirms “Neutral” Rating for Cogent Biosciences (NASDAQ:COGT) - Defense World
Cogent Biosciences Inc (COGT) Quarterly 10-Q Report - Quartzy
Cogent Biosciences (NASDAQ:COGT) Announces Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat
Needham & Company LLC Cuts Cogent Biosciences (NASDAQ:COGT) Price Target to $15.00 - MarketBeat
Cogent Biosciences Inc Reports Q3 2024 Net Loss Per Share of $0. - GuruFocus.com
Cogent Biosciences Reports Progress in Clinical Trials and Financial Standing - TipRanks
Cogent Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results - GlobeNewswire
Cogent Biosciences Reports Strong Pipeline Progress, $346M Cash Position Despite Q3 Losses | COGT Stock News - StockTitan
Creative Planning Buys 3,272 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences’ (COGT) Buy Rating Reaffirmed at HC Wainwright - Defense World
FMR LLC Acquires Additional Shares in Cogent Biosciences Inc - GuruFocus.com
(COGT) Trading Advice - Stock Traders Daily
Cogent Biosciences (NASDAQ:COGT) Trading Down 5.3%Here's What Happened - MarketBeat
Cogent Biosciences Announces Bezuclastinib Presentations at - GlobeNewswire
Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting - The Manila Times
Cogent Biosciences' (COGT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.67 Average PT from Brokerages - Defense World
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
(COGT) Investment Analysis - Stock Traders Daily
Hennion & Walsh Asset Management Inc. Purchases 44,287 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Cogent Biosciences' (COGT) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
Cogent Biosciences expands pipeline with KRAS inhibitor - Investing.com
Cogent Biosciences expands pipeline with KRAS inhibitor By Investing.com - Investing.com UK
Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics - StockTitan
Cogent Biosciences Announces Pipeline Expansion into KRAS - GlobeNewswire
COGT Stock Hits 52-Week High at $12.2 Amid Market Optimism - Investing.com India
Cogent Biosciences (NASDAQ:COGT) Sets New 52-Week HighHere's What Happened - MarketBeat
Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation - Yahoo Finance
SG Americas Securities LLC Acquires New Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
The Manufacturers Life Insurance Company Has $301,000 Stock Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Market Momentum Report: Cogent Biosciences Inc (COGT)’s Negative Close at 11.35 - The Dwinnex
Cogent Biosciences (NASDAQ:COGT) Shares Down 2.4%What's Next? - MarketBeat
(COGT) Technical Data - Stock Traders Daily
Stocks of Cogent Biosciences Inc (COGT) are poised to climb above their peers - SETE News
Cogent Biosciences (NASDAQ:COGT) Stock Price Up 4.6%Here's What Happened - MarketBeat
Did Cogent Biosciences Inc (COGT) perform well in the last session? - US Post News
Analysts Rate Cogent Biosciences, Inc. (COGT) as Moderate Buy with $15 Target - Insider Monkey
Get in on Cogent Biosciences Inc’s (COGT) buy-in window today! - SETE News
Metric Deep Dive: Understanding Cogent Biosciences Inc (COGT) Through its Ratios - The Dwinnex
코젠트 바이오사이언시스 (COGT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
2.08%
자본화:
|
볼륨(24시간):